2 suspended. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Suspended 2 |
| Phase 2 | 1 | Suspended 1 |
Follow palbociclib: new trials by email Literature Review of palbociclib trials Research Report on palbociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer APG-2575, Palbociclib - Breast Cancer, Solid Tumor, Adult | Phase 1 / Phase 2 | Suspended | Ascentage Pharma Group Inc. | 65 | 2021-08-13 | 2024-08-19 |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Palbociclib, Gedatolisib - Lung Cancer Squamous Cell, Solid Tumors | Phase 1 | Suspended | Dana-Farber Cancer Institute | 75 | 2017-02-28 | 2026-02-13 |
Breast Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Ascentage Pharma Group Inc. (1) · Dana-Farber Cancer Institute (1)
United States (2) · China (1)